Search hospitals > Oregon > Tualatin
Legacy Meridian Park Hospital
Claim this profileTualatin, Oregon 97062
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Recurrence
152 reported clinical trials
7 medical researchers
Summary
Legacy Meridian Park Hospital is a medical facility located in Tualatin, Oregon. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Legacy Meridian Park Hospital is involved with conducting 152 clinical trials across 292 conditions. There are 7 research doctors associated with this hospital, such as Andrew Y. Kee, Colleen C. McCormick, Mei Dong, and Jacqueline Vuky, MD.Area of expertise
1Cancer
Global LeaderStage IV
ER positive
Stage III
2Breast Cancer
Global LeaderER positive
HER2 positive
HER2 negative
Top PIs
Andrew Y. KeeLegacy Good Samaritan Hospital and Medical Center2 years of reported clinical research
Studies Lung Cancer
Studies Prostate Cancer
19 reported clinical trials
60 drugs studied
Colleen C. McCormickLegacy Good Samaritan Hospital and Medical Center4 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
13 reported clinical trials
44 drugs studied
Mei DongLegacy Good Samaritan Hospital and Medical Center1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
15 reported clinical trials
39 drugs studied
Jacqueline Vuky, MDOregon Health and Science University7 years of reported clinical research
Studies Cancer
Studies Non-Small Cell Lung Cancer
10 reported clinical trials
24 drugs studied
Clinical Trials running at Legacy Meridian Park Hospital
Breast Cancer
Prostate Cancer
Lung Cancer
Gallbladder Cancer
Non-Small Cell Lung Cancer
Ovarian Cancer
Fallopian Tube Cancer
Cancer
Rectal Cancer
Laryngeal Cancer
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Legacy Meridian Park Hospital?
Legacy Meridian Park Hospital is a medical facility located in Tualatin, Oregon. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Legacy Meridian Park Hospital is involved with conducting 152 clinical trials across 292 conditions. There are 7 research doctors associated with this hospital, such as Andrew Y. Kee, Colleen C. McCormick, Mei Dong, and Jacqueline Vuky, MD.